Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. reports news on the commercialization and development of photodynamic therapy in dermatology. The company’s core product platform includes Ameluz, an aminolevulinic acid hydrochloride topical gel used with the RhodoLED red-light lamp series, with an established focus on actinic keratoses and clinical programs addressing additional dermatologic conditions.
Recurring updates include financial results, U.S. commercial performance, clinical data for Ameluz PDT, FDA-related label-expansion activity, patent proceedings, and business updates tied to the company’s U.S. product rights, regulatory approvals, intellectual property, and manufacturing rights.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Biofrontera Inc. (NASDAQ:BFRI) announced the completion of the last patient visit in a Phase I study for Ameluz® - PDT aimed at treating mild to severe actinic keratosis (AK). The study, conducted by Biofrontera Bioscience GmbH, explored the safety and tolerability of using three tubes of BF-200 ALA 10% gel in expanded treatment fields. Top line results are anticipated in Q4 2023. CEO Erica Monaco emphasized this milestone as a significant advancement, potentially allowing broader treatment areas and fewer office visits for patients. Actinic keratosis is a common pre-cancerous condition affecting approximately 58 million U.S. residents, highlighting the importance of effective treatment options.
Biofrontera Inc. (NASDAQ:BFRI) announced a significant investment in expanding its salesforce by almost 30%, thereby increasing coverage to 40 territories in 2023. This strategic move aims to enhance outreach for their FDA-approved therapy for actinic keratosis, Ameluz®-PDT, further penetrating dermatology markets. CEO Erica Monaco highlighted the company’s success in 2022, achieving record revenues and market share with a reduced sales team. The addition of 140 years of healthcare experience is expected to bolster growth and market presence. The company remains optimistic about future performance despite potential challenges outlined in their forward-looking statements.
Biofrontera Inc. (NASDAQ:BFRI) is set to showcase its FDA-approved dermatological products at the 2023 American Academy of Dermatology (AAD) Annual Meeting from March 17-21 in New Orleans, LA. The company will demonstrate the photodynamic therapy (PDT) procedure using the RhodoLED lamp at booth #2224. CEO Erica Monaco stated the event is an opportunity to educate dermatologists about the Ameluz PDT therapy for treating actinic keratoses. The AAD Annual Meeting is the largest dermatologic event, attracting about 18,000 attendees, including around 10,000 medical personnel. Biofrontera aims to enhance its outreach among dermatology professionals during this major conference.
Summary not available.
Biofrontera (NASDAQ:BFRI) reported strong financial results for 2022, with total revenues reaching $28.7 million, a 19% increase from 2021. The fourth quarter revenues grew 11% year-over-year to $10.1 million. Notably, Ameluz revenues exceeded pre-COVID levels, increasing 12% from the 2019 record. The company plans to expand its sales force to 50-55 by 2025, aiming for a 25% revenue growth in 2023. Despite improving metrics, the net loss for 2022 narrowed to $640,000 from $37.7 million in 2021. Adjusted EBITDA remained negative at $18.1 million.